Medigene (FRA: MDG1)

Last close As at 11/10/2024

EUR1.85

−0.04 (−2.12%)

Market capitalisation

EUR28m

Medigene is a publicly listed, Germany-based, immuno-oncology platform company focused on the development of T cell receptor (TCR)-guided therapies with the aim of effectively eliminating cancer.

Latest Insights

Healthcare | edison tv

Medigene – executive interview

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Arron Aatkar

Analyst

Key Management

  • Dr Gerd Zettlmeissl

    Chairman

  • Dr Selwyn Ho

    CEO

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 4.3 (18.1) (41.9)
Relative (1.3) (21.7) (53.6)
52 week high/low €5.1/€1.7

Thematics

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

thematic

Healthcare

ASCO 2023 key takeaways

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free